Tagrisso granted Priority Review in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
20 October 2020 07:00 BST Tagrisso granted Priority Review in the US for the adjuvanttreatment of patients with early-stage EGFR-mutated lung cancer Unprecedented results show treatment with Tagrisso reduced the riskof disease recurrence or death by 80% in ADAURA Phase III trial AstraZeneca's Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung